Literature DB >> 29733871

Gut microbiota profiling in Han Chinese with type 1 diabetes.

Yun Huang1, Si-Cheng Li1, Ji Hu1, Hai-Bin Ruan2, He-Ming Guo1, Hong-Hong Zhang1, Xin Wang3, Yu-Fang Pei4, Yang Pan5, Chen Fang6.   

Abstract

AIMS: To investigate whether microbial dysbiosis is associated with T1D in Chinese population and to explore relationships between the composition of gut microbiome and clinical data.
METHODS: In this study, we recruited 10 healthy and 12 T1D Han Chinese subjects between the ages of 12 to 33. Fecal samples were collected for DNA extraction and 16S rRNA sequencing, followed by analyses of the gut microbiota composition.
RESULTS: Bacterial communities differed between healthy and T1D subjects. At the phylum level, Bacteroidetes and Firmicutes are the dominant phyla in T1D patients and healthy controls, respectively. The linear discriminant analysis (LDA) effect size (LEfSe) algorithm detected 28 bacterial taxonomic clades showing statistically differences (13 increased and 15 decreased) in T1D patients. Association analyses of clinical data and microbial community abundance demonstrated that abundances of Faecalibacterium were negatively correlated with HbA1c levels (Z = -2.614, P = 0.017). The numbers of detected anti-islet cell autoantibodies were positively correlated with Bacteriodes (Z = 2.531, P = 0.011) and Bilophila (Z = 2.477, P = 0.013) abundances, while negatively correlated with abundances of Streptococcus (Z = -2.041, P = 0.041) and Ruminococcaceae (Z = -2.23, P = 0.026).
CONCLUSIONS: These results suggest that Han Chinese T1D patients possess distinctly different gut microbiota, compared to healthy subjects, characterized by increased Bacteroidetes/Firmicutes ratio, negative correlation of Faecalibacterium abundance with HbA1c, and positive correlation of Bacteroides abundance with the presence of autoantibodies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-islet cell autoantibodies; Bacteroidetes; Firmicutes; Gut microbiota; Han Chinese; Type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29733871     DOI: 10.1016/j.diabres.2018.04.032

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  23 in total

1.  The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis.

Authors:  Xinyu Ge; Liang Zheng; Rulin Zhuang; Ping Yu; Zhican Xu; Guanya Liu; Xiaoling Xi; Xiaohui Zhou; Huimin Fan
Journal:  Adv Nutr       Date:  2020-01-01       Impact factor: 8.701

2.  Impact of Geographical Location on the Gut Microbiota Profile in Egyptian Children with Type 1 Diabetes Mellitus: A Pilot Study.

Authors:  Nahla M Elsherbiny; Mohammed Ramadan; Nagla H Abu Faddan; Elham Ahmed Hassan; Mohamed E Ali; Abeer Sharaf El-Din Abd El-Rehim; Wael A Abbas; Mohamed A A Abozaid; Ebtisam Hassanin; Ghada A Mohamed; Helal F Hetta; Mohammed Salah
Journal:  Int J Gen Med       Date:  2022-07-15

3.  Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults.

Authors:  Hanieh-Sadat Ejtahed; Zahra Hoseini-Tavassol; Shohre Khatami; Mehrangiz Zangeneh; Ava Behrouzi; Sara Ahmadi Badi; Arfa Moshiri; Shirin Hasani-Ranjbar; Ahmad-Reza Soroush; Farzam Vaziri; Abolfazl Fateh; Mostafa Ghanei; Saeid Bouzari; Shahin Najar-Peerayeh; Seyed Davar Siadat; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2020-02-08

Review 4.  Is there any association between gut microbiota and type 1 diabetes? A systematic review.

Authors:  Parnian Jamshidi; Saba Hasanzadeh; Azin Tahvildari; Yeganeh Farsi; Mahta Arbabi; João Felipe Mota; Leonardo A Sechi; Mohammad Javad Nasiri
Journal:  Gut Pathog       Date:  2019-10-14       Impact factor: 4.181

Review 5.  Targeting Gut Microbiota for the Prevention and Management of Diabetes Mellitus by Dietary Natural Products.

Authors:  Bang-Yan Li; Xiao-Yu Xu; Ren-You Gan; Quan-Cai Sun; Jin-Ming Meng; Ao Shang; Qian-Qian Mao; Hua-Bin Li
Journal:  Foods       Date:  2019-09-25

Review 6.  New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.

Authors:  Miriam Cabello-Olmo; Miriam Araña; Ilian Radichev; Paul Smith; Eduardo Huarte; Miguel Barajas
Journal:  Int J Mol Sci       Date:  2019-09-26       Impact factor: 5.923

Review 7.  Gut microbiota in pancreatic diseases: possible new therapeutic strategies.

Authors:  Li-Long Pan; Bin-Bin Li; Xiao-Hua Pan; Jia Sun
Journal:  Acta Pharmacol Sin       Date:  2020-10-22       Impact factor: 7.169

Review 8.  Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis.

Authors:  Mahdieh Abbasalizad Farhangi; Mahdi Vajdi; Mohammad Asghari-Jafarabadi
Journal:  Nutr J       Date:  2020-07-30       Impact factor: 3.271

Review 9.  Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

10.  Gut microbiota in early pregnancy among women with Hyperglycaemia vs. Normal blood glucose.

Authors:  Beibei Gao; Mengdan Zhong; Qiong Shen; Ying Wu; Mengdie Cao; Songwen Ju; Lei Chen
Journal:  BMC Pregnancy Childbirth       Date:  2020-05-11       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.